Nombre del producto:8-Fluoro-3,4-dihydro-1H-spiro[naphthalene-2,2'-[1,3]dioxolan]-6-ol

IUPAC Name:8'-fluoro-3',4'-dihydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalen]-6'-ol

CAS:2489407-88-5
Fórmula molecular:C12H13FO3
Pureza:95%
Número de catálogo:CM1046486
Peso molecular:224.23

Unidad de embalaje Stock disponible Precio($) Cantidad
CM1046486-1g in stock ǪǪƥľ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :2489407-88-5
Fórmula molecular:C12H13FO3
Punto de fusión:-
Código de sonrisas:FC1=C(CC2(CC3)OCCO2)C3=CC(O)=C1
Densidad:
Número de catálogo:CM1046486
Peso molecular:224.23
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Category Infos

Spiro Compounds
A spiro compound is a polycyclic compound in which two monocyclic rings share one carbon atom; the shared carbon atom is called a spiro atom. Spiro compounds have rigid structures, stable structures, and have special properties that general organic compounds do not possess, such as anomeric effect, spiro conjugation and spiro hyperconjugation. Compared with the monocyclic structure or the planar aromatic structure, the spiro structure has a larger three-dimensional structure; the heterocyclic spiro structure is also regarded as the biological isostere of some groups, which can change the drug to a certain extent. The water solubility, lipophilicity, dominant conformation and ADMET properties of the molecule make the optimized lead molecule easier to drug. Therefore, spiro compounds occupy a very important position in drug development.
Spiro And Bicyclic Compound
Hot sale various high quality spiro and bicyclic compound from china leading manufacturer. Our products are efficient, cost effective and deliver more benefits. welcome to choose us!

Column Infos

ABBV-CLS-484
Nature publishes discovery and preclinical results for ABBV-CLS-484, a potential first-in-class PTPN2/N1 inhibitor in cancer immunotherapy.
ABBV-CLS-484 is the first active-site phosphatase inhibitor to enter clinical evaluation as a cancer therapy and is currently in an AbbVie and Calico-led Phase 1 clinical trial in solid tumors.

Related Products